These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

581 related items for PubMed ID: 33980597

  • 1. Selective BCL-XL Antagonists Eliminate Infected Cells from a Primary-Cell Model of HIV Latency but Not from Ex Vivo Reservoirs.
    Ren Y, Huang SH, Macedo AB, Ward AR, Alberto WDC, Klevorn T, Leyre L, Copertino DC, Mota TM, Chan D, Truong R, Rohwetter T, Zumbo P, Dündar F, Betel D, Kovacs C, Benko E, Bosque A, Jones RB.
    J Virol; 2021 Jul 12; 95(15):e0242520. PubMed ID: 33980597
    [Abstract] [Full Text] [Related]

  • 2. BCL-2 antagonism sensitizes cytotoxic T cell-resistant HIV reservoirs to elimination ex vivo.
    Ren Y, Huang SH, Patel S, Alberto WDC, Magat D, Ahimovic D, Macedo AB, Durga R, Chan D, Zale E, Mota TM, Truong R, Rohwetter T, McCann CD, Kovacs CM, Benko E, Wimpelberg A, Cannon C, Hardy WD, Bosque A, Bollard CM, Jones RB.
    J Clin Invest; 2020 May 01; 130(5):2542-2559. PubMed ID: 32027622
    [Abstract] [Full Text] [Related]

  • 3. Bryostatin-1 Decreases HIV-1 Infection and Viral Production in Human Primary Macrophages.
    Hany L, Turmel MO, Barat C, Ouellet M, Tremblay MJ.
    J Virol; 2022 Feb 23; 96(4):e0195321. PubMed ID: 34878918
    [Abstract] [Full Text] [Related]

  • 4. Activation of Latent HIV-1 T Cell Reservoirs with a Combination of Innate Immune and Epigenetic Regulators.
    Palermo E, Acchioni C, Di Carlo D, Zevini A, Muscolini M, Ferrari M, Castiello L, Virtuoso S, Borsetti A, Antonelli G, Turriziani O, Sgarbanti M, Hiscott J.
    J Virol; 2019 Nov 01; 93(21):. PubMed ID: 31413127
    [Abstract] [Full Text] [Related]

  • 5. 4-Deoxyphorbol inhibits HIV-1 infection in synergism with antiretroviral drugs and reactivates viral reservoirs through PKC/MEK activation synergizing with vorinostat.
    De la Torre-Tarazona HE, Jiménez R, Bueno P, Camarero S, Román L, Fernández-García JL, Beltrán M, Nothias LF, Cachet X, Paolini J, Litaudon M, Alcami J, Bedoya LM.
    Biochem Pharmacol; 2020 Jul 01; 177():113937. PubMed ID: 32224142
    [Abstract] [Full Text] [Related]

  • 6. Modeling HIV-1 Latency Using Primary CD4+ T Cells from Virally Suppressed HIV-1-Infected Individuals on Antiretroviral Therapy.
    Takata H, Kessing C, Sy A, Lima N, Sciumbata J, Mori L, Jones RB, Chomont N, Michael NL, Valente S, Trautmann L.
    J Virol; 2019 Jun 01; 93(11):. PubMed ID: 30918072
    [Abstract] [Full Text] [Related]

  • 7. Class 1-Selective Histone Deacetylase (HDAC) Inhibitors Enhance HIV Latency Reversal while Preserving the Activity of HDAC Isoforms Necessary for Maximal HIV Gene Expression.
    Zaikos TD, Painter MM, Sebastian Kettinger NT, Terry VH, Collins KL.
    J Virol; 2018 Mar 15; 92(6):. PubMed ID: 29298886
    [Abstract] [Full Text] [Related]

  • 8. An In-Depth Comparison of Latency-Reversing Agent Combinations in Various In Vitro and Ex Vivo HIV-1 Latency Models Identified Bryostatin-1+JQ1 and Ingenol-B+JQ1 to Potently Reactivate Viral Gene Expression.
    Darcis G, Kula A, Bouchat S, Fujinaga K, Corazza F, Ait-Ammar A, Delacourt N, Melard A, Kabeya K, Vanhulle C, Van Driessche B, Gatot JS, Cherrier T, Pianowski LF, Gama L, Schwartz C, Vila J, Burny A, Clumeck N, Moutschen M, De Wit S, Peterlin BM, Rouzioux C, Rohr O, Van Lint C.
    PLoS Pathog; 2015 Jul 15; 11(7):e1005063. PubMed ID: 26225566
    [Abstract] [Full Text] [Related]

  • 9. Maraviroc Is Associated with Latent HIV-1 Reactivation through NF-κB Activation in Resting CD4+ T Cells from HIV-Infected Individuals on Suppressive Antiretroviral Therapy.
    Madrid-Elena N, García-Bermejo ML, Serrano-Villar S, Díaz-de Santiago A, Sastre B, Gutiérrez C, Dronda F, Coronel Díaz M, Domínguez E, López-Huertas MR, Hernández-Novoa B, Moreno S.
    J Virol; 2018 May 01; 92(9):. PubMed ID: 29444937
    [Abstract] [Full Text] [Related]

  • 10. The CCR5-antagonist Maraviroc reverses HIV-1 latency in vitro alone or in combination with the PKC-agonist Bryostatin-1.
    López-Huertas MR, Jiménez-Tormo L, Madrid-Elena N, Gutiérrez C, Rodríguez-Mora S, Coiras M, Alcamí J, Moreno S.
    Sci Rep; 2017 May 24; 7(1):2385. PubMed ID: 28539614
    [Abstract] [Full Text] [Related]

  • 11. PD-1 blockade potentiates HIV latency reversal ex vivo in CD4+ T cells from ART-suppressed individuals.
    Fromentin R, DaFonseca S, Costiniuk CT, El-Far M, Procopio FA, Hecht FM, Hoh R, Deeks SG, Hazuda DJ, Lewin SR, Routy JP, Sékaly RP, Chomont N.
    Nat Commun; 2019 Feb 18; 10(1):814. PubMed ID: 30778080
    [Abstract] [Full Text] [Related]

  • 12. HIV-1 Latency and Viral Reservoirs: Existing Reversal Approaches and Potential Technologies, Targets, and Pathways Involved in HIV Latency Studies.
    Khanal S, Schank M, El Gazzar M, Moorman JP, Yao ZQ.
    Cells; 2021 Feb 23; 10(2):. PubMed ID: 33672138
    [Abstract] [Full Text] [Related]

  • 13. Integrated Assessment of Viral Transcription, Antigen Presentation, and CD8+ T Cell Function Reveals Multiple Limitations of Class I-Selective Histone Deacetylase Inhibitors during HIV-1 Latency Reversal.
    Mota TM, McCann CD, Danesh A, Huang SH, Magat DB, Ren Y, Leyre L, Bui TD, Rohwetter TM, Kovacs CM, Benko E, MacLaren L, Wimpelberg A, Cannon CM, Hardy WD, Safrit JT, Jones RB.
    J Virol; 2020 Apr 16; 94(9):. PubMed ID: 32051267
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. HIV Persistence, Latency, and Cure Approaches: Where Are We Now?
    Chou TC, Maggirwar NS, Marsden MD.
    Viruses; 2024 Jul 19; 16(7):. PubMed ID: 39066325
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.